There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Pacira Pharmaceuticals (PCRX – Research Report), Biophytis (BPTS – Research Report) and Neurosense Therapeutics Ltd. (NRSN – Research Report) with bullish sentiments.
Pacira Pharmaceuticals (PCRX)
In a report released today, Serge Belanger from Needham maintained a Buy rating on Pacira Pharmaceuticals, with a price target of $76.00. The company’s shares closed last Wednesday at $51.47.
According to TipRanks.com, Belanger is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Pacira Pharmaceuticals with a $81.71 average price target.
See today’s best-performing stocks on TipRanks >>
Biophytis (BPTS)
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Biophytis, with a price target of $15.00. The company’s shares closed last Wednesday at $1.03, close to its 52-week low of $0.81.
According to TipRanks.com, Pantginis is ranked 0 out of 5 stars with an average return of
Biophytis has an analyst consensus of Moderate Buy, with a price target consensus of $15.00.
Neurosense Therapeutics Ltd. (NRSN)
In a report released yesterday, Naz Rahman from Maxim Group maintained a Buy rating on Neurosense Therapeutics Ltd., with a price target of $7.00. The company’s shares closed last Wednesday at $1.95, close to its 52-week low of $1.23.
According to TipRanks.com, Rahman has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on Neurosense Therapeutics Ltd. is a Moderate Buy with an average price target of $7.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on PCRX:
- Live Oak Bank Announces Lending Partnership with Ramp
- Needham Sticks to Its Buy Rating for Bicycle Therapeutics (BCYC)
- FOMO CORP. EXPANDS LEADERSHIP TEAM WITH EXPERIENCED OPERATIONAL EXECUTIVE; LAYS GROUNDWORK FOR FOUNDER’S TRANSITION
- Is My Ethereum Safe? What to Know Ahead of the Merge
- Psyence Group Announces Amendment and Closing of Previously Announced Private Placement
